p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). 1997

M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
Department of Experimental Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

In a previous study, we found that treatment of HCT-8 cells with ZD1694, a specific antifolate-based thymidylate synthase inhibitor, resulted in DNA fragmentation. In this study, we have demonstrated the dose- and time-dependent induction of DNA fragmentation accompanied by elevation of p53 and WAF1 protein expression by ZD1694. WAF1 mRNA showed a time-dependent increase, whereas p53 mRNA was not found to be significantly overexpressed. The initial increase in WAF1 mRNA was detected at 4 hr, but increased WAF1 protein expression was detected 8-24 hr after a 2-hr exposure. The amount of total and hypophosphorylated pRb seems to be rising greatly after ZD1694 exposure. The effects of ZD1694 on the expression of E2F1 and formation of the E2F1-Rb complex were investigated after a 2-hr drug exposure (IC90). The results showed a time-dependent decrease in E2F1 mRNA and protein expression; an increase in the abundance of the E2F-Rb complex could be demonstrated beginning 4 hr after drug exposure by a gel shift assay. Kinetic analysis showed increased availability of hypophosphorylated pRb for inhibition of E2F, which could indirectly result from WAF1-induced inhibition cyclin-dependent kinase activity. Whereas thymidylate synthase inhibition by ZD1694 was rapid in onset and maintained for at least 24 hr after drug treatment, drug-induced cellular growth inhibition was significant 24 hr after drug exposure. The increased abundance of hypophosphorylated pRb and binding to transcription factor E2F-1 is consistent with ZD1694-induced cell growth inhibition in HCT-8 cells. Therefore, the observed effect on downstream events after effective inhibition of thymidylate synthase may offer the critical determinants of response to ZD1694.

UI MeSH Term Description Entries
D007078 Ileal Neoplasms Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL). Cancer of ILEUM,Cancer of the ILEUM,Cancer, Ileal,Ileal Cancer,Cancers, Ileal,ILEUM Cancer,ILEUM Cancers,Ileal Cancers,Ileal Neoplasm,Neoplasm, Ileal,Neoplasms, Ileal
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
January 1995, European journal of cancer (Oxford, England : 1990),
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
October 1995, Journal of the National Cancer Institute,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
May 1995, British journal of cancer,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
July 1998, Cancer research,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
February 1996, Annals of oncology : official journal of the European Society for Medical Oncology,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
February 1999, Experimental cell research,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
August 1996, British journal of cancer,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
January 1998, British journal of cancer,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
March 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M B Yin, and W Voigt, and A Panadero, and U Vanhoefer, and C Frank, and S Pajovic, and J Azizkhan, and Y M Rustum
January 1997, Tumori,
Copied contents to your clipboard!